DZ Bank’s Travere Therapeutics TVTX Stock Holding History

DZ Bank’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-54,500	Closed	-$1.22M	–	1083
2018 Q1	$1.22M	Buy	+54,500	New	+$1.3M	﹤0.01%	621

Other funds holding TVTX

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

DZ Bank's TVTX Position: Q2 2018 in Review

DZ Bank sold out of Travere Therapeutics (TVTX) in Q2 2018, closing a stake of 54,500 shares — an estimated $1.22M sold.

DZ Bank first reported a position in TVTX in Q1 2018 and held it in 1 quarter. The position peaked at $1.22M in Q1 2018. 129 funds tracked by Wall St. Rank hold TVTX as of Q2 2018.

DZ Bank reported no remaining Travere Therapeutics position as of Q2 2018 after selling out during the quarter.
DZ Bank sold 54,500 Travere Therapeutics shares in Q2 2018, an estimated $1.22M.
DZ Bank first reported a position in Travere Therapeutics in Q1 2018 and held it in 1 quarter.
DZ Bank's Travere Therapeutics position peaked at $1.22M in Q1 2018.
129 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2018.

Based on DZ Bank's 13F filing for Q2 2018, filed 14 Aug 2018.